Watkins v. Morgan et al

On February 20, 2025, Marcus Watkins filed a class-action lawsuit against Dr. Alistair Morgan and BioGenix Labs in California. Watkins, a former participant in a clinical trial for a genetic therapy targeting Huntington's disease, alleged that BioGenix and its lead scientist, Dr. Morgan, deliberately altered the experimental viral vector without disclosure. The unapproved modification supposedly intended to enhance cognitive functions caused severe neurological damage in over 30 subjects. The suit claims the defendants bypassed FDA oversight, falsified consent forms, and concealed adverse effects. The case rapidly escalated into a major civil rights and medical ethics scandal.

Pending trial. A preliminary injunction has frozen all BioGenix assets and prohibited further use of the modified vector. The court granted class certification for all affected trial participants.

The central dispute is whether BioGenix Labs and Dr. Morgan committed battery and fraud by intentionally modifying a gene therapy trial without informed consent, and whether the unapproved experiment that caused neurological harm constitutes a violation of fundamental human rights and federal safety regulations.

The case triggered congressional hearings on FDA oversight gaps in gene-editing trials, caused a sharp decline in biotechnology stock values, and sparked global ethical debates on human enhancement. It led to a 30% drop in clinical trial enrollment nationwide and prompted an emergency WHO summit on genetic research governance.